Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41
about
Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regionsThree-dimensional solution structure of the 44 kDa ectodomain of SIV gp41Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts.Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusionThe Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core ComplexCharacterization of a Structural Intermediate of Flavivirus Membrane FusionA fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesViral membrane fusionInhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusionInteractions between HIV-1 gp41 core and detergents and their implications for membrane fusionStructural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.Mutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complexDesign of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to ResistanceDistinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesCrystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41Viral membrane fusion.The synthetic peptide derived from the NH2-terminal extracellular region of an orphan G protein-coupled receptor, GPR1, preferentially inhibits infection of X4 HIV-1Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop regionSensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptorEvidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug targetA synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusionAsymmetric deactivation of HIV-1 gp41 following fusion inhibitor bindingA role for nephrin, a renal protein, in vertebrate skeletal muscle cell fusionEvidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusionA specific point mutant at position 1 of the influenza hemagglutinin fusion peptide displays a hemifusion phenotypeThe avian retrovirus avian sarcoma/leukosis virus subtype A reaches the lipid mixing stage of fusion at neutral pH.Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41.Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediateThe lipid-anchored ectodomain of influenza virus hemagglutinin (GPI-HA) is capable of inducing nonenlarging fusion poresGenetic control of fusion pore expansion in the epidermis of Caenorhabditis elegans.Pinpointing retrovirus entry sites in cells expressing alternatively spliced receptor isoforms by single virus imaging.Measles virus entry inhibitors: a structural proposal for mechanism of action and the development of resistance.Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cellsEstimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage.Identification of the HIV-1 gp41 core-binding motif--HXXNPF.Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1.The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.
P2860
Q21090508-E69FE689-4155-4F06-9884-66CF260EE27FQ24533287-535ED1FE-073F-4D94-B235-CC5CECDFA633Q24791794-66A909AC-C1BC-435B-8FB5-7EAF1959F50DQ27469663-31D6F96B-E950-4C06-AAFC-D8353E029595Q27469690-28127BE5-D2E1-46D9-B2BA-190DA64E01A6Q27477706-B74347F0-DF44-46CE-B4D8-559F9AE0446CQ27478061-2384ACA4-7CD0-464D-9B39-D917F57F0F26Q27485578-4F699A3C-6B2B-460E-BF9C-A8AD98E9B964Q27486639-8553B074-2FDF-49EA-9FF1-82FE73E6BE17Q27619600-C665B819-0438-4889-B1D8-3C7E920FF5B0Q27620993-13B10F62-0710-4108-BCAC-C2C9AF1C0AFEQ27635422-35F58393-67F2-4EA8-8D3E-CE0931E81A0EQ27637675-CE2FF6F7-25FB-4B5A-AE43-C98A7BC969C3Q27664086-A949F151-FC89-4689-9F34-899A4E1A47F9Q27665884-DBA6CADB-63D3-4664-B6CD-BC9B193C80B4Q27666159-E3985462-F185-495A-9FF8-9813C52CDA03Q28080422-C23312C4-56B9-43FA-9E9D-8BF8487A3463Q28253096-3B6B1660-4C63-446F-96D8-0580B46E40E2Q28343496-A4F5F949-7AA2-45CA-87D4-A867AE20DE03Q28343901-F3EBCA24-F787-411D-B014-FC74E3FA28B6Q28346124-6EC01E31-3A8A-4C3C-9C60-A0653C23E635Q28369397-5C8184AD-C61C-4ECE-8C0C-1F1FE78F3055Q28379574-D4A1C71C-E728-4204-A921-EF442E1852A4Q28471980-7F511C0B-CA58-4B56-BA83-CE0E4F881D8DQ28507874-BEE21EB1-D526-4C4C-8A6C-0D13215565A6Q28646673-9AC7E070-1AA5-403B-8F3B-37EE253573C6Q30304191-D9F68981-30DF-4CEB-A91C-D4CB5E4018FAQ30310511-E59C4BF3-8F98-481F-9DE5-35FF5945B550Q30426201-26AFE743-2736-4E5C-BB43-73D791A0AD6BQ30448708-04CF11D1-48DA-413B-8123-2FBADC048377Q30454458-8D2A9825-C47C-4924-92D9-3C3D1F489F32Q30479203-4A9816DC-8612-4CA2-8644-7D34256C0B40Q30581160-BE79BF49-B101-4BC7-A1D5-BCB98EA5AAC9Q30583105-6F3BB30F-ECF9-4A0A-B499-11444105D93FQ30865013-84140150-B760-46D8-BA2B-7C5C5AC5C959Q31151010-A52A2B23-4797-4E43-82F3-648805CA68B9Q31454800-C983B804-A6B0-4CB6-BCDE-636F57AD99BDQ33253687-2AF8F4FE-CABD-4BDB-85D8-BD075A190E5BQ33267982-0954AECF-48F6-449D-BABB-43A145634AC9Q33269255-55A93591-1DEB-43C4-A463-D55611538225
P2860
Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Dilation of the human immunode ...... a synthetic peptide from gp41
@ast
Dilation of the human immunode ...... a synthetic peptide from gp41
@en
type
label
Dilation of the human immunode ...... a synthetic peptide from gp41
@ast
Dilation of the human immunode ...... a synthetic peptide from gp41
@en
prefLabel
Dilation of the human immunode ...... a synthetic peptide from gp41
@ast
Dilation of the human immunode ...... a synthetic peptide from gp41
@en
P2093
P2860
P356
P1476
Dilation of the human immunode ...... a synthetic peptide from gp41
@en
P2093
I Muñoz-Barroso
K Sakaguchi
R Blumenthal
P2860
P304
P356
10.1083/JCB.140.2.315
P407
P577
1998-01-01T00:00:00Z